Switzerland
  • /
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • People
  • US
  • UK
  • Germany
  • France
  • Africa
  • CH
  • @

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • /
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • People
  • US
  • UK
  • Germany
  • France
  • Africa
  • CH
  • @

Browsing Tag

alternative complement pathway

4 posts
NNovartis
Can Novartis' Fabhalta Strengthen Its Nephrology Franchise?
Read More

Can Novartis’ Fabhalta Strengthen Its Nephrology Franchise?

  • 2026-07-17
Novartis NVS announced that the FDA has granted traditional approval to Fabhalta (iptacopan) for slowing kidney function decline…
NNovartis
FDA grants traditional approval to Novartis’ Fabhalta for IgAN
Read More

FDA grants traditional approval to Novartis’ Fabhalta for IgAN

  • 2026-07-17
The US Food and Drug Administration (FDA) has issued traditional approval to Novartis for Fabhalta (iptacopan), to slow…
NNovartis
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
Read More

Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN

  • 2026-07-17
Novartis Pharma AG Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 …
NNovartis
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
Read More

Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN

  • 2026-07-16
Novartis Pharma AG Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 …
Switzerland
www.europesays.com